ST
CLDX icon

Spot Trading’s Celldex Therapeutics CLDX Stock Holding History

Spot Trading’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-343
Closed -$23K – 3112
2016
Q2 		$23K Sell
343
-480
-58% -$30.5K ﹤0.01% 2952
2016
Q1 		$47K Buy
+823
New +$92.6K ﹤0.01% 2828
2015
Q4 		– Sell
-554
Closed -$88K – 3650
2015
Q3 		$88K Buy
+554
New +$157K ﹤0.01% 3100
2015
Q2 		– Sell
-681
Closed -$285K – 3894
2015
Q1 		$285K Buy
+681
New +$244K ﹤0.01% 2517
2014
Q3 		– Sell
-651
Closed -$142K – 4354
2014
Q2 		$159K Buy
+651
New +$147K ﹤0.01% 3473
2013
Q3 		– Sell
-93
Closed -$31.9K – 4133
2013
Q2 		$22K Buy
+93
New +$18.3K ﹤0.01% 3853

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Spot Trading's CLDX Position: Q3 2016 in Review

Spot Trading sold out of Celldex Therapeutics (CLDX) in Q3 2016, closing a stake of 343 shares — an estimated $23K sold.

Spot Trading first reported a position in CLDX in Q2 2013 and held it in 6 quarters. The position peaked at $285K in Q1 2015. 139 funds tracked by Wall St. Rank hold CLDX as of Q3 2016.

  • Spot Trading reported no remaining Celldex Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Spot Trading sold 343 Celldex Therapeutics shares in Q3 2016, an estimated $23K.
  • Spot Trading first reported a position in Celldex Therapeutics in Q2 2013 and held it in 6 quarters.
  • Spot Trading's Celldex Therapeutics position peaked at $285K in Q1 2015.
  • 139 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2016.

Based on Spot Trading's 13F filing for Q3 2016, filed 31 Oct 2016.